What is a stock summary page? Click here for an overview.
Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd
NAICS : 325412
ISIN : CNE100001M79
Share Class Description:
STU:08HH: Class HCompare
Compare
Traded in other countries / regions
600196.China02196.Hong KongSFOSF.USA08HH.Germany IPO Date
2014-10-28Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.45 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.77 | |||||
| Debt-to-EBITDA | 6.46 | |||||
| Interest Coverage | 2.24 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.45 | |||||
| Beneish M-Score | -2.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.3 | |||||
| 3-Year EBITDA Growth Rate | -1.7 | |||||
| 3-Year EPS without NRI Growth Rate | -12.1 | |||||
| 3-Year Book Growth Rate | 5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 19.68 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.73 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.38 | |||||
| 9-Day RSI | 59.31 | |||||
| 14-Day RSI | 56.27 | |||||
| 3-1 Month Momentum % | 12.41 | |||||
| 6-1 Month Momentum % | 8.46 | |||||
| 12-1 Month Momentum % | 28.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.92 | |||||
| Quick Ratio | 0.73 | |||||
| Cash Ratio | 0.43 | |||||
| Days Inventory | 126.55 | |||||
| Days Sales Outstanding | 70.41 | |||||
| Days Payable | 106.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.89 | |||||
| Dividend Payout Ratio | 0.27 | |||||
| 3-Year Dividend Growth Rate | -14.4 | |||||
| Forward Dividend Yield % | 1.89 | |||||
| 5-Year Yield-on-Cost % | 1.89 | |||||
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | -1.96 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.97 | |||||
| Operating Margin % | 7.8 | |||||
| Net Margin % | 6.75 | |||||
| FCF Margin % | 0.17 | |||||
| ROE % | 5.93 | |||||
| ROA % | 2.41 | |||||
| ROIC % | 2.59 | |||||
| 3-Year ROIIC % | 1.7 | |||||
| ROC (Joel Greenblatt) % | 22.26 | |||||
| ROCE % | 7.08 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.76 | |||||
| Forward PE Ratio | 11.23 | |||||
| PE Ratio without NRI | 25.34 | |||||
| Shiller PE Ratio | 19.51 | |||||
| PEG Ratio | 13.34 | |||||
| PS Ratio | 1.67 | |||||
| PB Ratio | 1.46 | |||||
| Price-to-Tangible-Book | 4.27 | |||||
| Price-to-Free-Cash-Flow | 1072.92 | |||||
| Price-to-Operating-Cash-Flow | 15.29 | |||||
| EV-to-EBIT | 17.06 | |||||
| EV-to-Forward-EBIT | 23.15 | |||||
| EV-to-EBITDA | 17.06 | |||||
| EV-to-Forward-EBITDA | 14.23 | |||||
| EV-to-Revenue | 2.33 | |||||
| EV-to-Forward-Revenue | 1.53 | |||||
| EV-to-FCF | 1393.09 | |||||
| Price-to-GF-Value | 0.95 | |||||
| Price-to-Projected-FCF | 2.66 | |||||
| Price-to-DCF (Earnings Based) | 1.21 | |||||
| Price-to-DCF (FCF Based) | 61.13 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Price-to-Graham-Number | 2.24 | |||||
| Earnings Yield (Greenblatt) % | 5.86 | |||||
| FCF Yield % | 0.11 | |||||
| Forward Rate of Return (Yacktman) % | -7.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Fosun Pharmaceutical (Group) Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5,279.836 | ||
| EPS (TTM) (€) | 0.133 | ||
| Beta | 0.95 | ||
| 3-Year Sharpe Ratio | -0.38 | ||
| 3-Year Sortino Ratio | -0.59 | ||
| Volatility % | 30.03 | ||
| 14-Day RSI | 56.27 | ||
| 14-Day ATR (€) | 0.034229 | ||
| 20-Day SMA (€) | 1.78185 | ||
| 12-1 Month Momentum % | 28.51 | ||
| 52-Week Range (€) | 1.32 - 2.318 | ||
| Shares Outstanding (Mil) | 2,671.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Fosun Pharmaceutical (Group) Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Fosun Pharmaceutical (Group) Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Fosun Pharmaceutical (Group) Co Ltd Frequently Asked Questions
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd(STU:08HH)'s stock price today?
The current price of STU:08HH is €1.83. The 52 week high of STU:08HH is €2.32 and 52 week low is €1.32.
When is next earnings date of Shanghai Fosun Pharmaceutical (Group) Co Ltd(STU:08HH)?
The next earnings date of Shanghai Fosun Pharmaceutical (Group) Co Ltd(STU:08HH) is .
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd(STU:08HH) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Fosun Pharmaceutical (Group) Co Ltd(STU:08HH) is 1.89% (As of Today), Highest Dividend Payout Ratio of Shanghai Fosun Pharmaceutical (Group) Co Ltd(STU:08HH) was 0.56. The lowest was 0.27. And the median was 0.37. The  Forward Dividend Yield % of Shanghai Fosun Pharmaceutical (Group) Co Ltd(STU:08HH) is 1.89%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers